miR-10b and miR-223-3p in serum microvesicles signal progression from prediabetes to type 2 diabetes

  • M. Parrizas
  • X. Mundet
  • C. Castaño
  • S. Canivell
  • X. Cos
  • L. Brugnara
  • C. Giráldez-García
  • E. Regidor
  • M. Mata-Cases
  • J. Franch-NadalEmail author
  • A. NovialsEmail author
Original Article



Type 2 diabetes frequently remains undiagnosed for years, whereas early detection of affected individuals would facilitate the implementation of timely and cost-effective therapies, hence decreasing morbidity. With the intention of identifying novel diagnostic biomarkers, we characterized the miRNA profile of microvesicles isolated from retroactive serum samples of normoglycemic individuals and two groups of subjects with prediabetes that in the following 4 years either progressed to overt diabetes or remained stable.


We profiled miRNAs in serum microvesicles of a selected group of control and prediabetic individuals participating in the PREDAPS cohort study. Half of the subjects with prediabetes were diagnosed with diabetes during the 4 years of follow-up, while the glycemic status of the other half remained unchanged.


We identified two miRNAs, miR-10b and miR-223-3p, which target components of the insulin signaling pathway and whose ratio discriminates between these two subgroups of prediabetic individuals at a stage at which other features, including glycemia, are less proficient at separating them. In global, the profile of miRNAs in microvesicles of prediabetic subjects primed to progress to overt diabetes was more similar to that of diabetic patients than the profile of prediabetic subjects who did not progress.


We have identified a miRNA signature in serum microvesicles that can be used as a new screening biomarker to identify subjects with prediabetes at high risk of developing diabetes, hence allowing the implementation of earlier, and probably more effective, therapeutic interventions.


Prediabetes Progression Diagnosis Microvesicle Biomarker MicroRNA 



We are indebted to the IDIBAPS Biobank, integrated in the Spanish National Biobank Network, for the sample and data procurement. We are grateful to Yaiza Esteban and Lucía-Isabel Alvarado for technical support. We acknowledge the PREDAPS Study investigators: Gabriel Cuatrecasas (EAP Sarria SL), Eduard Tarragó (EAP Bellvitge), M. Isabel Bobé (EAP La Mina), Flora Lopez (EAP Martorell), Martí Birules (EAP Poble Nou), Rosamar DeMiguel (EAP Pubilla Casas), Laura Romera (EAP Raval Nord), Ana Martinez-Sanchez (EAP El Carmel), Belén Benito, Beatriz Bilbeny and Neus Piulachs (EAP Raval Sud).

Author contributions

MP and AN designed the study; XM, XC, SC, LB, CGG, ER, MMC and JFN performed data collection and clinical analysis; CC and MP performed exosome isolation and RNA analysis; SC, MP and CC performed statistical analyses; MP wrote the first draft of the manuscript; all authors provided critical revisions of the manuscript.


This work was supported by grants EFSD/Lilly and an unrestricted grant from Novartis awarded to AN. It also received support from CIBERDEM.

Compliance with ethical standards

Conflict of interest

No potential conflicts of interest relevant to this article were disclosed.

Ethical approval

The study was approved by the Ethical Committees of Parc de Salut Mar Clinical of Barcelona (Register 2011/4274/I) and the Hospital Clinic, University of Barcelona (Register 2011/6945).

Informed consent

Written informed consent was obtained from all the participants included in this study, in accordance with the principles of the Declaration of Helsinki.


  1. 1.
    Cho NH, Shaw JE, Karuranga S et al (2018) IDF diabetes atlas. Diabetes Res Clin Pract 138:271–281. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Soriguer F, Goday A, Bosch-Comas A et al (2012) Prevalence of diabetes mellitus and impaired glucose regulation in Spain: study. Diabetologia 55:88–93. CrossRefPubMedGoogle Scholar
  3. 3.
    Mata-Cases M, Casajuana M, Franch-Nadal J et al (2016) Direct medical costs attributable to type 2 diabetes: a population-based study in Catalonia, Spain. Eur J Health Econ 17:1001–1010. CrossRefPubMedGoogle Scholar
  4. 4.
    Müller G (2012) Microvesicles/exosomes as potential novel biomarkers of metabolic diseases. Diabetes Metab Syndr Obes Targets Ther 5:247–282. CrossRefGoogle Scholar
  5. 5.
    Pirola L, Balcerczyk A, Okabe J, El-Osta A (2010) Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 6:665–675. CrossRefPubMedGoogle Scholar
  6. 6.
    Párrizas M, Novials A (2016) Circulating microRNAs as biomarkers for metabolic disease. Best Pract Res Clin Endocrinol Metab 30:591–601. CrossRefPubMedGoogle Scholar
  7. 7.
    Bartel DP (2018) Metazoan microRNAs. Cell 173:20–51CrossRefGoogle Scholar
  8. 8.
    Castaño C, Novials A, Párrizas M (2019) Exosomes and diabetes. Diabetes Metab Res Rev 2019:e3107. CrossRefGoogle Scholar
  9. 9.
    Párrizas M, Brugnara L, Esteban Y et al (2015) Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention. J Clin Endocrinol Metab 100:E407–E415. CrossRefPubMedGoogle Scholar
  10. 10.
    Thomou T, Mori MA, Dreyfuss JM et al (2017) Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature 542:450–455. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ying W, Riopel M, Bandyopadhyay G et al (2017) Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell 171:372–384. CrossRefPubMedGoogle Scholar
  12. 12.
    Castaño C, Kalko S, Novials A, Párrizas M (2018) Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. Proc Natl Acad Sci 115:12158–12163. CrossRefPubMedGoogle Scholar
  13. 13.
    Diaz-Redondo A, Giraldez-Garcia C, Carrillo L et al (2015) Modifiable risk factors associated with prediabetes in men and women: cross-sectional analysis of the cohort study in primary health care on the evolution of patients with prediabetes (PREDAPS). BMC Fam Pract 16:5. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Franch-Nadal J, Caballeria L, Mata-Cases M et al (2018) Fatty liver index is a predictor of incident diabetes in patients with prediabetes: PREDAPS study. PLoS One 13:1–17. CrossRefGoogle Scholar
  15. 15.
    Giráldez-García C, Franch-Nadal J, Sangrós FJ et al (2018) Adiposity and diabetes risk in adults with prediabetes: heterogeneity of findings depending on age and anthropometric measure. Obesity 26:1481–1490. CrossRefPubMedGoogle Scholar
  16. 16.
    Bedogni G, Bellentani S, Miglioli L et al (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33. CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402–408. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Tirosh A, Shai I, Tekes-Manova D et al (2005) Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 353:1454–1462. CrossRefPubMedGoogle Scholar
  19. 19.
    Wang K, Yuan Y, Cho JH et al (2012) Comparing the microRNA spectrum between serum and plasma. PLoS One 7:e41561. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gong Q, Gregg EW, Wang J et al (2011) Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: China Da Qing Diabetes Prevention Outcome Study. Diabetologia 54:300–307. CrossRefPubMedGoogle Scholar
  21. 21.
    Lindstrom J, Peltonen M, Eriksson JG et al (2013) Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study. Diabetologia 56:284–293. CrossRefPubMedGoogle Scholar
  22. 22.
    He Y, Ding Y, Liang B et al (2017) A systematic study of dysregulated microRNA in type 2 diabetes. Int J Mol Sci 18:456. CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Liang YZ, Li JJH, Xiao HB et al (2018) Identification of stress-related microRNA biomarkers in type 2 diabetes: a systematic review and meta-analysis. J Diabetes. CrossRefPubMedGoogle Scholar
  24. 24.
    Lund AH (2010) miR-10 in development and cancer. Cell Death Differ 17:209–214. CrossRefPubMedGoogle Scholar
  25. 25.
    Zhao X, Chen Z, Zhou Z et al (2019) High-throughput sequencing of small RNAs and analysis of differentially expressed microRNAs associated with high-fat diet-induced hepatic insulin resistance in mice. Genes Nutr 14:6. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Herrera BM, Lockstone HE, Taylor JM et al (2010) Global miRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 53:1099–1109. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Wen D, Qiao P, Wang L (2015) Circulating miR-223 as a potential biomarker for obesity. Obes Res Clin Pract 9:398–404. CrossRefPubMedGoogle Scholar
  28. 28.
    Ye D, Zhang T, Lou G, Liu Y (2018) Role of miR-223 in the pathophysiology of liver diseases. Exp Mol Med 50:128. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Aziz F (2016) The emerging role of miR-223 as novel potential diagnostic and therapeutic target for inflammatory disorders. Cell Immunol 303:1–6. CrossRefPubMedGoogle Scholar
  30. 30.
    Hay N (2011) Akt isoforms and glucose homeostasis. Trends Endocrinol Metab 22:66–73. CrossRefPubMedGoogle Scholar
  31. 31.
    Fabre A, Marchal S, Barlogis V et al (2019) Clinical aspects of STAT3 gain-of-function germline mutations. J Allergy Clin Immunol Pract 7:1958–1969. CrossRefPubMedGoogle Scholar
  32. 32.
    Kung C-P, Murphy ME (2016) The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol 231:R61–R75. CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Moldovan L, Batte KE, Trgovcich J et al (2014) Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med 18:371–390. CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Venturella M, Carpi FM, Zocco D (2019) Standardization of blood collection and processing for the diagnostic use of extracellular vesicles. Curr Pathobiol Rep. CrossRefGoogle Scholar
  35. 35.
    Blondal T, Jensby Nielsen S, Baker A et al (2013) Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 59:164–169. CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2019

Authors and Affiliations

  1. 1.Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM)BarcelonaSpain
  2. 2.Pathogenesis and Prevention of Diabetes LaboratoryAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS)BarcelonaSpain
  3. 3.redGDPS FoundationMadridSpain
  4. 4.DAP-Cat Group, Research Support UnitUniversity Institute for Research in Primary Care Jordi Gol (IDIAPJGol)BarcelonaSpain
  5. 5.Autonomous University of BarcelonaBarcelonaSpain
  6. 6.Primary Health Care Center Sant Martí de Provençals, Catalan Health InstituteBarcelonaSpain
  7. 7.Department of Internal MedicineHealth Sciences Research Institute and University Hospital Germans Trias i PujolBarcelonaSpain
  8. 8.Preventive Medicine ServiceUniversity Hospital Infanta ElenaMadridSpain
  9. 9.Preventive Medicine, Public Health and History of Science DepartmentComplutense University of MadridMadridSpain
  10. 10.Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP)MadridSpain
  11. 11.Health Research Institute, Hospital Clínico San Carlos (IdISSC)MadridSpain
  12. 12.Primary Health Care Center La Mina, Catalan Health InstituteSant Adrià De Besòs, BarcelonaSpain
  13. 13.Department of MedicineUniversity of BarcelonaBarcelonaSpain

Personalised recommendations